ranolazine umedica 500mg tableta s prodlouženým uvolňováním
umedica netherlands b.v., amsterdam array - 10704 ranolazin - tableta s prodlouženým uvolňováním - 500mg - ranolazin
ranolazine umedica 750mg tableta s prodlouženým uvolňováním
umedica netherlands b.v., amsterdam array - 10704 ranolazin - tableta s prodlouženým uvolňováním - 750mg - ranolazin
bufomix easyhaler 320mcg/9mcg prášek k inhalaci
orion corporation, espoo array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - prášek k inhalaci - 320mcg/9mcg - formoterol a budesonid
symbicort 160mcg/4,5mcg suspenze k inhalaci v tlakovém obalu
astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - suspenze k inhalaci v tlakovém obalu - 160mcg/4,5mcg - formoterol a budesonid
symbicort 80mcg/2,25mcg suspenze k inhalaci v tlakovém obalu
astrazeneca ab, södertälje array - 5362 budesonid; 14188 dihydrÁt formoterol-fumarÁtu - suspenze k inhalaci v tlakovém obalu - 80mcg/2,25mcg - formoterol a budesonid
neofordex
theravia - dexamethason - mnohočetný myelom - kortikosteroidy pro systémové použití - léčba mnohočetného myelomu.
rikalpa 1mcg měkká tobolka
av medical cz s.r.o., praha array - 15512 parikalcitol - měkká tobolka - 1mcg - parikalcitol
rikalpa 2mcg měkká tobolka
av medical cz s.r.o., praha array - 15512 parikalcitol - měkká tobolka - 2mcg - parikalcitol
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - léky na obstrukční onemocnění dýchacích cest, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - léky na obstrukční onemocnění dýchacích cest, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).